# Supplemental information

# An immunogenomic signature for molecular

classification in hepatocellular carcinoma

Weiwei Zhuang, Hongwei Sun, Shanshan Zhang, Yilin Zhou, Wanqing Weng, Boda Wu, Tingbo Ye, Weiguo Huang, Zhuo Lin, Liang Shi, and Keqing Shi

Supplementary Figure 1. Cross-validation of IL7R and IL18RAP in prognosis of hepatocellular carcinoma using Kaplan-Meier Plotter and GEO (GSE 14520) databases.

(A) IL7R in Kaplan-Meier Plotter databases; (B) IL18RAP in Kaplan-Meier Plotter databases; (C) IL7R in GSE 14520; (D) IL18RAP in GSE 14520

Supplementary Figure 2. The expression levels of IL7R and IL18RAP in randomly selected hepatocellular carcinoma samples.

Table S1. The clinicopathological characteristics of the three cohorts

Variables	Subgroups	Development set (N=44)
Age		
	<60	28
	≧60	16
Gender		
	Male	37
	Female	7
HBV infection		
	Positive	31
	Negative	13
HCV infection		
	Positive	0
	Negative	44
AFP		
	<300ng/mL	30
	≥300ng/mL	14
CA19-9		
	<20U/ml	26
	≥20U/ml	15
	Unknow	3
Total bilirubin		
	<21umol/L	36
	≥21umol/L	8
ALT		
	>50U/L	16
	≤50U/L	28
AST		
	>50U/L	14
	≤50U/L	30
GGT		
	>50U/L	22
	≤50U/L	22
Degree of tumor differentiation		
	Poorly	4
	Poorly moderately	9
	Moderately	19
	Moderately well	2
	Well	3
	Unknow	7
TNM stage		
	Stage I	14
	Stage II	8
	Stage III a	2

	Stage III b	1
	Stage III c	6
	Stage IV	2
	Unknow	11
Tumor range		
	I	14
	II	10
	III	3
	IV	5
	Unknow	12
Lymphatic metastasis		
	Yes	10
	No	24
	Unknow	10
Remote metastasis		
	Yes	2
	No	30
	Unknow	12
Liver cirrhosis		
	Yes	28
	No	16
Diabetes		
	Yes	8
	No	36
Relapse		
	Yes	28
	No	16
Survival status		
	Dead	19
	Living	25